SOLICITATION NOTICE
Q -- Autoantibody responses against tumor-associated antigens (TAAs) and ovarian cancer in a case-control study conducted in Poland; and a nested case-control study within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
- Notice Date
- 8/24/2015
- Notice Type
- Presolicitation
- NAICS
- 541690
— Other Scientific and Technical Consulting Services
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02CP52695-61
- Archive Date
- 9/23/2015
- Point of Contact
- KATHY D. ELLIOTT, Phone: 240-276-5570, Seena Ninan, Phone: 240-276-5419
- E-Mail Address
-
ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov
(ELLIOTTK@MAIL.NIH.GOV, ninans@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- The National Cancer Institute (NCI), Division of Cancer Epidemiology & Genetics (DCEG) plans to procure on a sole source basis services for Autoantibody responses against tumor-associated antigens (TAAs) and ovarian cancer in a case-control study conducted in Poland; and a nested case-control study within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial from Virus-Host Interactions of Polyoma and Papilloma Viruses Division of Genome Modifications and Carcinogenesis (F020), Research Program Infection and Cancer German Cancer Research Center (DKFZZ), Im Neuenheimer Feld 280, 69120 Heidelberg, Germany. This acquisition will be processed in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(1) and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 541690 and the business size standard is $14.0 Million. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance is twelve (12) months from date of award. It has been determined there are no opportunities to acquire green products or services for this procurement. The National Cancer Institute propose to conduct a set of studies to comprehensively test for possible relations between antibody responses against tumor-associated antigens (TAAs) and ovarian cancer in serum samples from a previously conducted population-based case-control study in Poland with further evaluation in prospectively collected samples from a nested case-control study in the PLCO Cancer Screening Trial. It has been well established that immune responses against self-antigens can occur in cancer patients, likely initiated by alterations in the tumor itself that result in increased immunogenicity of self-antigens. Several antigens have been identified that are expressed in tumor cells that are non-existent or present at very low levels in normal cells; therefore, may function as tumor-associated antigens (TAAs) capable of priming the immune system to recognize tumor cells. With the use of recently developed and validated multiplex assay, NCI will analyze humoral immune responses against 50 TAAs in 864 samples (in 278 ovarian cancer cases, 556 controls, and 30 blinded quality control samples from archived specimens that were conducted in a population-based case-control study in Poland. In order to determine utility as early detection markers, NCI will analyze these same TAAs in prediagnostic specimens from 158 ovarian cancer cases, 158 matched controls, and 17 quality control samples in a nested case-control study in the PLCO screening trial. The Contractor shall perform the following tasks. 1. Conduct Luminex-based multiplex serology assay to quantify antibody response to 50 TAAs in 864 samples (278 ovarian cancer cases, 556 controls, 30 blinded quality control samples) from archived specimens from the ovarian cancer case-control study in Poland. 2. Provide an interim report on the preliminary results 2 weeks after initiating the analysis of serum samples. This report will include information on the quality of the antibody response measurements (including CVs) ascertained to date, and to report the antibody response measurements from the serum samples ascertained to date. 3. Provide the antibody response quantitation data on all 864 samples run by the contractor in each batch, in an accessible format (such as.xlsx,.dta, or.csv) no later than 12 months from the date of the award. 4. Conduct Luminex-based multiplex serology assay to quantify antibody response to 30 TAAs in 333 samples (158 ovarian cancer cases, 158 controls, 17 blinded quality control samples) from the NCI PLCO Cancer Screening Trial. 5. Provide an interim report on the preliminary results 2 weeks after initiating the analysis of serum samples. This report will include information on the quality of the antibody response measurements (including CVs) ascertained to date, and to report the antibody response measurements from the serum samples ascertained to date. 6. Provide the antibody response quantitation data on all 333 samples run by the contractor in each batch, in an accessible format (such as.xlsx,.dta, or.csv) no later than 12 months from the date of the award. 7. All biological materials provided by the U.S. Government, all residual specimens, and all data generated shall be the property of the U.S. Government. The Virus-Host Interactions of Polyoma and Papilloma Viruses Division of Genome Modifications and Carcinogenesis (F020), Research Program Infection and Cancer German Cancer Research Center (DKFZZ) have developed a reliable high throughput multiplex assay to measure antibody responses against tumor-associated antigens (TAAs). These assays detect antibodies directed in as little as 50 ul serum or plasma. The assays are very sensitive and give quantitative results over a wide dynamic range. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 11:00AM EST, on September 8, 2015. All responses and questions must be in writing and faxed 240-276-5401 or emailed to Kathy Elliott, Contract Specialist via electronic mail at Elliottk@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, contractors must be registered and have valid certification in the System for Award Management (SAM) through sam.gov. Reference: N02CP52695-61 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02CP52695-61/listing.html)
- Place of Performance
- Address: 9609 Medical Center Drive, Bethesda, Maryland, 20892, United States
- Zip Code: 20892
- Zip Code: 20892
- Record
- SN03851805-W 20150826/150824234924-ae6238c49806115a8a41f56af087bd0a (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |